Lung cancer tester Biodesix makes preliminary IPO filing

BOULDER — Lung-cancer genetics tester Biodesix Inc. has filed a preliminary prospectus for an initial public offering.

In filings with the U.S. Securities and Exchange Commission Friday afternoon, the Boulder company said it plans to go public in the Nasdaq Global Market under the symbol “BDSX.”

The filing is preliminary and lacks key information such as the amount of money it is looking to raise, the target range for its stock price at debut and the timing of those stocks hitting the open market.

Biodesix creates tests that analyze lung-cancer samples to determine if specific genes have mutated to cause the malignant tumors, in turn offering specific strategies for doctors and patients.

It has spent much of this year pivoting to creating and processing COVID-19 tests, including for Major League Lacrosse’s shortened season and as an expanded capacity lab for Colorado State University.

In the filings, Biodesix said it expects that it can capture part of the $27 billion annual market for lung-cancer continuum-of-care in the U.S.

The company revealed that it had $24.55 million in sales at the end of 2019, compared with $20.43 million the year before. However, its net losses increased from $26.16 million in 2018 to $30.72 million last year.

In the first half of 2020, Biodesix brought in $9.33 million in revenue, but posted net losses of $17.97 million. It has $11.67 million in cash and equivalents on hand.

ArcherDX Inc., another Boulder company in the genetic assay industry, filed for a $100 million IPO in June before accepting a $1.4 billion acquisition offer from Invitae Inc. (NYSE: NVTA) weeks later.

Biodesix said it may face initial risks due to the ongoing COVID-19 pandemic because cancer patients may be limited in the doctors and providers they have access to, and it has received fewer lung-cancer samples than usual when the crisis hit en masse in late March.

However, biotechnology stocks have been some of the strongest performers in the IPO market this year, specifically because demand for treatments in cancer and other chronic and deadly diseases hasn’t been cancelled by the pandemic.

A Biodesix spokesperson declined to comment Friday. Companies are generally prohibited from most public communications between filing a public offering prospectus and shortly after it goes public.

 

© 2020 BizWest Media LLC

BOULDER — Lung-cancer genetics tester Biodesix Inc. has filed a preliminary prospectus for an initial public offering.

In filings with the U.S. Securities and Exchange Commission Friday afternoon, the Boulder company said it plans to go public in the Nasdaq Global Market under the symbol “BDSX.”

The filing is preliminary and lacks key information such as the amount of money it is looking to raise, the target range for its stock price at debut and the timing of those stocks hitting the open market.

Biodesix creates tests that analyze lung-cancer samples to determine if specific genes have mutated to cause the malignant tumors, in turn offering specific strategies for doctors and patients.

It has spent much of this year pivoting to creating and processing COVID-19 tests, including for Major League Lacrosse’s shortened season and as an expanded capacity lab for Colorado State University.

In the filings, Biodesix said it expects that it can capture part of the $27 billion annual market for lung-cancer continuum-of-care in the U.S.

The company revealed that it had $24.55 million in sales at the end of 2019, compared with $20.43 million the year before. However, its net losses increased from $26.16 million in 2018 to $30.72 million last year.

In the first half of 2020, Biodesix brought in $9.33 million in revenue, but posted net losses of $17.97 million. It has $11.67 million in cash and equivalents on hand.

ArcherDX Inc., another Boulder company in the genetic assay industry, filed for a $100 million IPO

This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.

Want to See More!?

Login

OR

 

Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!

MOST POPULAR
Print + Digital Subscription
Online access PLUS print versions of all Bizwest publications
$8 per month

One month subscription includes:

  • 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
  • 1-month subscription to BizWest & all of the publications in print version.

DIGITAL ONLY
Digital Subscription
Online access for one year.
$8 per month

One month subscription includes:

  • 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.

VIP ACCESS
Unlimited Subscription
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
$300 per year

One year subscription includes:

  • 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
  • 1-year subscription to BizWest & all of the publications in print version.
  • 1-year premium online access to unlimited downloads from the BizWest Datastore!
  • 1-year premium online access to the ALL NEW Breaking Ground website!

PREMIUM ACCESS
Breaking Ground Subscription
Unlimited access PLUS premium access to our all new BreakingGround site!
$15 per month

One month subscription includes:

  • 14-day FREE trial!
  • 1-month of premium online access to the ALL NEW Breaking Ground website!
  • 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
  • 1-month subscription to BizWest & all of the publications in print version.

PREMIUM ACCESS - ANNUAL
Breaking Ground Subscription
Unlimited access PLUS premium access to our all new BreakingGround site!
$165 one year

One year subscription includes:

  • 14-day FREE trial!
  • 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
  • 1-year subscription to BizWest & all of the publications in print version.
  • 1-year premium online access to the ALL NEW Breaking Ground website!

Your promotional subscription will automatically renew at the full rate on the date of your subscription maturity. Reminder notices will be emailed before each auto-renewing payment to the email address on file. You may cancel at any time by calling (970) 232-3143 or emailing bdennis@bizwest.com. Your BizWest subscription also includes a complimentary subscription to the BizWest email newsletter, and you may easily unsubscribe from this at any time by emailing bdennis@bizwest.com.